Source: Virtual Congress 2021 – Inhaled treatments for COPD: clinical trials and real-world studies



Rating:

Share or cite this content

Citations should be made in the following way:
L. Bjermer (Lund, Sweden), C. Vogelmeier (Marburg, Germany), E. Kerwin (Medford, OR, United States of America), I. Boucot (Brentford, Middlesex, United Kingdom), F. Maltais (Québec, QC, Canada), L. Tombs (Brentford, Middlesex, United Kingdom), C. Compton (Brentford, Middlesex, United Kingdom), D. Lipson (Collegeville and Philadelphia, PA, United States of America), P. Jones (Brentford, Middlesex, United Kingdom). Improvements in lung function with umeclidinium/vilanterol analysed by reversibility at screening: a post hoc analysis of the EMAX trial. 797

Member's Comments

No comment yet.

Related content which might interest you: Efficacy of aclidinium/formoterol: pooled post hoc analysis of patients naïve to COPD maintenance therapy Source: International Congress 2017 – COPD management Year: 2017 Symptom improvement over time with umeclidinium/vilanterol versus monotherapy: a post-hoc analysis of the EMAX trial Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019 Impact of turnaround time on outcome with point-of-care testing for respiratory viruses: a post hoc analysis from a randomised controlled trial Source: Eur Respir J, 52 (2) 1800555; 10.1183/13993003.00555-2018 Year: 2018 Characterising patients with COPD by baseline short-acting ß2-agonist (SABA) use: a post hoc analysis of the EMAX trial Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more Year: 2020 Treatment response in COPD: does FEV1 say it all? A post hoc analysis of the CRYSTAL study Source: ERJ Open Res, 5 (1) 00243-2018; 10.1183/23120541.00243-2018 Year: 2019 Impact of grouping patients by 2017 GOLD strategy assessment criteria: a post hoc analysis of the TONADO and OTEMTO trials Source: International Congress 2017 – COPD management: new findings from large studies Year: 2017 Correlation between clinic and remote FEV1 and FeNO measurements; post hoc analysis of the INCONTRO study Source: Virtual Congress 2020 – Exhaled biomarkers of asthma and the asthma burden Year: 2020 Predictors of loss of asthma control in the Phase 2a INCONTRO trial: A post-hoc analysis Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights Year: 2020 Nintedanib in IPF: post hoc analysis of the Italian FIBRONET observational study Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries Year: 2020 The impact of grouping patients by the 2017 GOLD COPD strategy on response to therapy: post hoc results from the TONADO tiotropium+olodaterol trials Source: International Congress 2017 – What is new in COPD diagnosis and classification? Year: 2017 Circulating desmosine as a biomarker of azithromycin treatment response: a post hoc analysis of the COLUMBUS randomised controlled trial Source: ERJ Open Res, 4 (4) 00136-2018; 10.1183/23120541.00136-2018 Year: 2018 Mometasone/ indacaterol/ glycopyrronium demonstrates similar efficacy in men and women: post hoc analysis of IRIDIUM study Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence Year: 2021 Dyspnoea and clinical outcome in critically ill patients receiving noninvasive support for COVID-19 respiratory failure: post hoc analysis of a randomised clinical trial Source: ERJ Open Res, 7 (4) 00418-2021; 10.1183/23120541.00418-2021 Year: 2021 ICS withdrawal and exacerbation risk by GOLD 2017 Report: post hoc analysis of the WISDOM trial Source: International Congress 2018 – Primary care management of respiratory conditions Year: 2018 Application of machine learning algorithms to predict loss of asthma control: A post-hoc analysis of INCONTRO study Source: Virtual Congress 2020 – Clinical characteristics and diagnostic tools for phenotyping asthma and COPD Year: 2020 Indacaterol/glycopyrronium (IND/GLY) reduces the risk of clinically important deterioration (CID) versus open-label tiotropium (Tio) in COPD patients: Post hoc analysis from SHINE and SPARK studies Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Clinical significance of serum SP-D as a biomarker for antifibrotics in idiopathic pulmonary fibrosis (IPF): Post hoc analysis of a phase 3 trial of pirfenidone in Japan Source: International Congress 2019 – Biomarkers and beyond in idiopathic interstitial pneumonia Year: 2019 Modelling peripheral blood eosinophils to identify response to budesonide in COPD: a post-hoc analysis Source: International Congress 2017 – Current challenges in COPD evaluation Year: 2017 Workstation 2 – Spirometry: performing the test, safety measures, selecting the best values and simulating errors Source: International Congress 2014 – EW9 Spirometry knowledge and basic skills (European spirometry training programme) Year: 2014 Workstation 2 – Spirometry: performing the test, safety measures, selecting the best values and simulating errors Source: International Congress 2014 – EW8 Spirometry knowledge and basic skills (European spirometry training programme) Year: 2014